Share This Article:

Chemosensitivity Testing of Circulating Epithelial Tumor Cells (CETC) in Vitro: Correlation to in Vivo Sensitivity and Clinical Outcome

Abstract Full-Text HTML XML Download Download as PDF (Size:1047KB) PP. 597-605
DOI: 10.4236/jct.2013.42077    4,039 Downloads   6,703 Views   Citations

ABSTRACT

Background: Chemotherapy is a mainstay of tumor therapy, however, it is predominantly applied according to empirically developed recommendations derived from statistical relapse rates occurring years after the treatment in the adjuvant situation and from progression-free interval data in the metastatic situation, without any possibility of individually determining the efficacy in the adjuvant situation and with loss of time and quality of life in the metastatic situation if the drugs chosen are not effective. Here, we present a method to determine the efficiency of chemotherapeutic drugs using tumor cells circulating in blood as the part of the tumor actually available in the patient’s body for chemosensitivity testing. Methodology/Principal Findings: After only red blood cell lysis, omitting any enrichment (analogous to other blood cell enumeration methods, including rare CD34 cells), the white cells comprising the circulating epithelial tumor cells (CETC) are exposed to the drugs in question in different concentrations and for different periods of time. Staining with a fluorescence-labeled anti-epithelial antibody detects both vital and dying tumor cells, distinguishing vital from dying cells through membrane permeability and nuclear staining with propidium iodide. Increasing percentages of dying tumor cells are observed dependent on time and concentration. The sensitivity can vary during therapy and was correlated with decrease or increase in CETC and clinical outcome. Conclusions/Significance: Thus, we are able to show that chemosensitivity testing of circulating tumor cells provides real-time information about the sensitivity of the tumor present in the patient, even at different times during therapy, and correlates with treatment success.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

N. Rudiger, E. Stein, E. Schill, G. Spitz, C. Rabenstein, M. Stauch, M. Rengsberger, I. Runnebaum, U. Pachmann and K. Pachmann, "Chemosensitivity Testing of Circulating Epithelial Tumor Cells (CETC) in Vitro: Correlation to in Vivo Sensitivity and Clinical Outcome," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 597-605. doi: 10.4236/jct.2013.42077.

References

[1] O. Camara, M. Rengsberger, A. Egbe, A. Koch, M. Gajda, U. Hammer, C. Jorke, C. Rabenstein, M. Untch and K. Pachmann, “The Relevance of Circulating Epithelial Tumour Cells (CETC) for Therapy Monitoring during Neoadjuvant (Primary Systemic) Chemotherapy in Breast Cancer,” Annals of Oncology, Vol. 18, No. 9, 2007, pp. 1484-1492. doi:10.1093/annonc/mdm206
[2] G. Bonadonna, A. Moliterni, M. Zambetti, M. G. Daidone, S. Pilotti, L. Gianni and P. Valagussa, “30 Years’ Follow Up of Randomised Studies of Adjuvant CMF in Operable Breast Cancer: Cohort Study,” British Medical Journal, Vol. 330, No. 7485, 2005, p. 217. doi:10.1136/bmj.38314.622095.8F
[3] E. Colomb and P. M. Martin, “Testing of a Chemosensitivity Screening Method on Sensitive and Resistant Breast Tumoral Epithelial Cell Lines,” Analytical Cellular Pathology, Vol. 6, No. 2, 1994, pp. 105-116.
[4] F. X. Han, H. Lin and L. Ru, “MTT Assay for Detecting 5-Fluorouracil Chemosensitivity of Human Breast Carcinoma Cell Line,” Journal of Southern Medical University, Vol. 29, No. 1, 2009, pp. 97-99.
[5] T. P. Dawson, R. V. Iyer, R. W. Lea, P. Roberts, E. Harris, K. Ashton, A. Golash and C. H. Davis, “The MTS vs. the ATP Assay for in Vitro Chemosensitivity Testing of Primary Glioma Tumour Culture,” Neuropathology and Applied Neurobiology, Vol. 36, No. 6, 2010, pp. 564-567. doi:10.1111/j.1365-2990.2010.01096.x
[6] K. Brigulová, M. Cervinka, J. Tosner and I. Sedláková, “Chemoresistance Testing of Human Ovarian Cancer Cells and Its in Vitro Model,” Toxicology in Vitro, Vol. 24, No. 8, 2010, pp. 2108-2115. doi:10.1016/j.tiv.2010.08.010
[7] P. J. Schuler, S. Trellakis, J. Greve, M. Bas, C. Bergmann, E. Bolke, G. Lehnerdt, S. Mattheis, A. E. Albers, S. Brandau, S. Lang, T. L. Whiteside, H. Bier and T. K. Hoffmann, “In Vitro Chemosensitivity of Head and Neck Cancer Cell Lines,” European Journal of Medical Research, Vol. 15, No. 8, 2010, pp. 337-344. doi:10.1186/2047-783X-15-8-337
[8] A. M. Otto, M. Brischwein, H. Grothe, E. Motrescu and B. Wolf, “Multiparametric Sensor Chips for Chemosensitivity Testing of Sensitive and Resistant Tumor Cells,” Recent Results in Cancer Research, Vol. 161, 2003, pp. 39-47. doi:10.1007/978-3-642-19022-3_4
[9] S. Ugurel, D. Schadendorf, C. Pfohler, K. Neuber, A. Thoelke, J. Ulrich, A. Hauschild, K. Spieth, M. Kaatz, W. Rittgen, S. Delorme, W. Tilgen, U. Reinhold and Dermatologic Cooperative Oncology Group, “In Vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group,” Clinical Cancer Research, 2006, Vol. 12, No. 18, pp. 5454-5463. doi:10.1158/1078-0432.CCR-05-2763
[10] T. Wakatsuki, A. Irisawa, H. Imamura, M. Terashima, G. Shibukawa, T. Takagi, Y. Takahashi, A. Sato, M. Sato, T. Ikeda, R. Suzuki, T. Hikichi, K. Obara and H. Ohira, “Complete Response of Anaplastic Pancreatic Carcinoma to Paclitaxel Treatment Selected by Chemosensitivity Testing,” International Journal of Clinical Oncology, Vol. 15, No. 3, 2010, pp. 310-313. doi:10.1007/s10147-010-0038-9
[11] T. Wakatsuki, A. Irisawa, M. Terashima, G. Shibukawa, T. Takagi, H. Imamura, Y. Takahashi, A. Sato, M. Sato, T. Ikeda, R. Suzuki, T. Hikichi, K. Obara and H. Ohira, “ATP Assay-Guided Chemosensitivity Testing for Gemcitabine with Biopsy Specimens Obtained from unresectable Pancreatic Cancer Using Endoscopic Ultrasonography-Guided Fine-Needle Aspiration,” International Journal of Clinical Oncology, Vol. 16, No. 4, 2011, pp. 387-394. doi:10.1007/s10147-011-0197-3
[12] B. U. Sevin and J. P. Perras, “Tumor Heterogeneity and in Vitro Chemosensitivity Testing in Ovarian Cancer,” American Journal of Obstetrics and Gynecology, Vol. 176, No. 4, 1997, pp. 759-768. doi:10.1016/S0002-9378(97)70599-4
[13] T. J. Herzog, T. C. Krivak, A. N. Fader and R. L. Coleman, “Chemosensitivity Testing with ChemoFx and Overall Survival in Primary Ovarian Cancer,” American Journal of Obstetrics and Gynecology, Vol. 203, No. 1, 2010, pp. 68.e1-6.
[14] Z. Q. Ling, C. J. Qi, X. X. Lu, L. J. Qian, L. H. Gu, Z. G. Zheng, Q. Zhao, S. Wang, X. H. Fang, Z. X. Yang, J. Yin and W. M. Mao, “Heterogeneity of Chemosensitivity in Esophageal Cancer Using ATP-Tumor Chemosensitivity Assay,” Acta Pharmacolpgoca Sinica, Vol. 33, No. 3, 2010, pp. 401-406. doi:10.1038/aps.2011.195
[15] I. Vergote, C. G. Tropé, F. Amant, G. B. Kristensen, T. Ehlen, N. Johnson, R. H. Verheijen, M. E. van der Burg, A. J. Lacave, P. B. Panici, G. G. Kenter, A. Casado, C. Mendiola, C. Coens, L. Verleye, G. C. Stuart, S. Pecorelli, N. S. Reed, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group and NCIC Clinical Trials Group, “Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer,” New England Journal of Medicine, Vol. 363, No. 10, 2010, pp. 943-953. doi:10.1056/NEJMoa0908806
[16] J. Aigner, A. Schneeweiss, C. Sohn and F. Marmé, “The Role of Neoadjuvant Chemotherapy in the Management of Primary Breast Cancer,” Minerva Ginecologica, Vol. 63, No. 3, 2011, pp. 261-274.
[17] M. Untch, P. A. Fasching, G. E. Konecny, S. Hasmüller, A. Lebeau, R. Kreienberg, O. Camara, V. Müller, A. du Bois, T. Kühn, E. Stickeler, N. Harbeck, C. Hoss, S. Kahlert, T. Beck, W. Fett, K. M. Mehta, G. von Minckwitz and S. Loibl, “Complete Response after Neoadjuvant Chemo-Therapy plus Trastuzumab Predicts Favourable Survival in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: Results from the TECHNO Trial of the AGO and GBG Study Groups,” Journal of Clinical Oncology, 2011, Vol. 29, No. 25, pp. 3351-3357. doi:10.1200/JCO.2010.31.4930
[18] C. Liedtke, C. Mazouni, K. R. Hess, F. André, A. Tordai, J. A. Mejia, W. F. Symmans, A. M. Gonzalez-Angulo, B. Hennessy, M. Green, M. Cristofanilli, G. N. Hortobagyi and L. Pusztai, “Response to Neoadjuvant Therapy and LongTerm Survival in Patients with Triple-Negative Breast Cancer,” Journal of Clinical Oncology, Vol. 26, No. 8, 2008, pp. 1275-1281. doi:10.1200/JCO.2007.14.4147
[19] C. Shimizu, N. Masuda, K. Yoshimura, H. Tsuda, M. Mano, M. Ando, K. Tamura and Y. Fujiwara, “LongTerm Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer,” Japanese Journal of Clinical Oncology, Vol. 39, No. 8, 2009, pp. 484-490. doi:10.1093/jjco/hyp052
[20] T. Karn, L. Pusztai, U. Holtrich, T. Iwamoto, C. Y. Shiang, M. Schmidt, V. Müller, C. Solbach, R. Gaetje, L. Hanker, A. Ahr, C. Liedtke, E. Ruckhaberle, M. Kaufmann and A. Rody, “Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures,” PLoS One, Vol. 6, No. 12, 2012, Article ID: e28403. doi:10.1371/journal.pone.0028403
[21] M. Gajda, O. Camara, S. Oppel, T. Kroll, C. Jorke, S. Krauspe, U. Hammer, C. Rabenstein, M. Untch, I. B. Runnebaum and K. Pachmann, “Monitoring Circulating Epithelial Tumor Cells (CETC) during Primary Systemic Chemotherapy Including Trastuzumab for Early Prediction of Outcome in Patients with Her2/neu-Positive Tumors,” Annals of Oncology, Vol. 19, No. 12, 2008, pp. 2090-2091. doi:10.1093/annonc/mdn648
[22] Z. Panteleakou, P. Lembessis, A. Sourla, N. Pissimissis, A. Polyzos, C. Deliveliotis and M. Koutsilieris, “Detection of Circulating Tumor Cells in Prostate Cancer Patients: Methodological Pitfalls and Clinical Relevance,” Molecular Medicine, Vol. 15, No. 3-4, 2009, pp. 101-114.
[23] S. Mortazavi, F. A. Ardalan, S. R. Nodehi, F. F. Karder and N. Miraliakbari, “True Volumetric Method for Flow Cytometric Enumeration of CD34 + Stem Cells and Its Agreement with a Standard Bead-Based Single-Platform Protocol,” Cytotherapy, Vol. 14, No. 5, 2012, pp. 621-629. doi:10.3109/14653249.2012.667875
[24] K. Pachmann, J. H. Clement, C. P. Schneider, B. Willen, O. Camara, U. Pachmann and K. Hoffken, “Standardized Quantification of Circulating Peripheral Tumor Cells from Lung and Breast Cancer,” Clinical Chemistry and Laboratory Medicine, Vol. 43, No. 6, 2005, pp. 617-627. doi:10.1515/CCLM.2005.107
[25] U. Pachmann, K. Hekimian, S. Carl, N. Ruediger, C. Rabenstein and K. Pachmann, “Comparing Sequential Steps for Detection of Circulating Tumor Cells: More Specific or Just Less Sensitive?” WebmedCentral CANCER, Vol. 2, No. 2, 2011, Article ID: WMC001490.
[26] K. Pachmann, O. Camara, A. Kavallaris, S. Krauspe, N. Malarski, M. Gajda, T. Kroll, C. Jorke, U. Hammer, A. Altendorf-Hofmann, C. Rabenstein, U. Pachmann, I. Runnebaum and K. H?ffken, “Monitoring the Response of Circulating Epithelial Tumor Cells (CETC) to Adjuvant Chemotherapy in Breast Cancer Allows Detection of Patients at Risk of Early Relapse,” Journal of Clinical Oncology, Vol. 26, No. 6, 2008, pp. 1208-1215. doi:10.1200/JCO.2007.13.6523
[27] O. Camara, M. Rengsberger, A. Egbe, A. Koch, M. Gajda, U. Hammer, C. Jorke, C. Rabenstein, M. Untch and K. Pachmann, “The Relevance of Circulating Epithelial Tumour Cells (CETC) for Therapy Monitoring during Neoadjuvant (Primary Systemic) Chemotherapy in Breast Cancer,” Annals of Oncology, Vol. 18, No. 9, 2007, pp. 1484-1492. doi:10.1093/annonc/mdm206
[28] K. Pachmann, O. Camara, A. Kohlhase, C. Rabenstein, T. Kroll, I. B. Runnebaum and K. Hoeffken, “Assessing the Efficacy of Targeted Therapy Using Circulating Epithelial Tumor Cells (CETC): The Example of SERM Therapy Monitoring as a Unique Tool to Individualize Therapy,” Journal of Cancer Research and Clinical Oncology, Vol. 137, No. 5, 2011, pp. 821-828. doi:10.1007/s00432-010-0942-4
[29] K. Pachmann, O. Camara, T. Kroll, M. Gajda, A. K. Gellner, J. Wotschadlo and I. B. Runnebaum, “Efficacy Control of Therapy Using Circulating Epithelial Tumor Cells (CETC) as ‘Liquid Biopsy’: Trastuzumab in HER2/neuPositive Breast Carcinoma,” Journal of Cancer Research and Clinical Oncology, Vol. 137, No. 9, 2011, pp. 1317-1327. doi:10.1007/s00432-011-1000-6
[30] J. C. Davila, C. G. Reddy, P. J. Davis and D. Acosta, “Toxicity Assessment of Papaverine Hydrochloride and Papaverine-Derived Metabolites in Primary Cultures of Rat Hepatocytes,” In Vitro Cellular and Developmental Biology, Vol. 26, No. 5, 1990, pp. 515-524. doi:10.1007/BF02624095
[31] N. Rasmussen, J. H. Andersen, H. Jespersena, O. G. Mouritsen and H. J. Ditzel, “Effect of Free Fatty Acids and Lysolipids on Cellular Uptake of Doxorubicin in Human Breast Cancer Cell Lines,” Anti-Cancer Drugs, Vol. 21, No. 7, 2010, pp. 674-677.
[32] V. K. Sondak, C. A. Bertelsen, N. Tanigawa, S. U. Hildebrand-Zanki, D. L. Morton, E. L. Korn and D. H. Kern, “Clinical Correlations with Chemosensitivities Measured in a Rapid Thymidine Incorporation Assay,” Cancer Research, Vol. 44, No. 4, 1984, pp. 1725-1728.
[33] H. Eidtmann, W. Jonat and H. Maass, “Drug Sensitivity Testing of Gynecologic Tumors Using Volm’s Test and Stem Cell Assay,” Geburtshilfe und Frauenheilkunde, Vol. 45, No. 7, 1985, pp. 477-481. doi:10.1055/s-2008-1036356
[34] J. M. Lyons 3rd, J. Abergel, J. L. Thomson, C. T. Anthony, Y. Z. Wang, L. B. Anthony, J. P. Boudreaux, J. Strauchen, M. Idrees, R. R. Warner and E. A. Woltering, “In Vitro Chemoresistance Testing in Well-Differentiated Carcinoid Tumors,” Annals of Surgical Oncology, Vol. 16, No. 3, 2009, pp. 649-655. doi:10.1245/s10434-008-0261-z
[35] J. Komen, F. Wolbers, H. R. Franke, H. Andersson, I. Vermes and A. van den Berg, “Viability Analysis and Apoptosis Induction of Breast Cancer Cells in a Microfluidic Device: Effect of Cytostatic Drugs,” Biomedical Microdevices, Vol. 10, No. 5, 2008, pp. 727-737. doi:10.1007/s10544-008-9184-5
[36] Z. Li, H. P. Song, W. S. He, Y. Tian and T. Huang, “In Vitro Chemosensitivity Testing of Primary and Recurrent Breast Carcinomas and Its Clinical Significance,” Journal of Huazhong University of Science and Technology, Vol. 28, No. 6, 2008, pp. 683-687. doi:10.1007/s11596-008-0616-5
[37] A. M. Otto, M. Brischwein, A. Niendorf, T. Henning, E. Motrescu and B. Wolf, “Microphysiological Testing for Chemosensitivity of Living Tumor Cells with Multiparametric Microsensor Chips,” Cancer Detection and Prevention, Vol. 27, No. 4, 2003, pp. 291-296. doi:10.1016/S0361-090X(03)00093-X
[38] C. M. Kurbacher and I. A. Cree, “Chemosensitivity Testing Using Microplate Adenosine Triphosphate-Based Luminescence Measurements,” Methods in Molecular Medicine, Vol. 110, 2005, pp. 101-120.
[39] F. X. Han, H. Lin and L. Ru, “MTT Assay for Detecting 5-Fluorouracil Chemosensitivity of Human Breast Carcinoma Cell Line,” Journal of Southern Medical University, Vol. 29, No. 1, 2009, pp. 97-99.
[40] P. Gazzaniga, G. Naso, A. Gradilone, E. Cortesi, O. Gandini, W. Gianni, M. A. Fabbri, B. Vincenzi, F. di Silverio, L. Frati, A. M. Aglianò and M. Cristofanilli, “Chemosensitivity Profile Assay of Circulating Cancer Cells: Prognostic and Predictive Value in Epithelial Tumors,” International Journal of Cancer, Vol. 126, No. 10, 2010, pp. 2437-2447.
[41] G. I. Lau, W. T. Loo and L. W. C. Chow, “Neoadjuvant Chemotherapy for Breast Cancer Determined by Chemosensitivity Assay Achieves Better Tumor Response,” Biomedicine and Pharmacotherapy, Vol. 61, No. 9, 2007, pp. 562-565. doi:10.1016/j.biopha.2007.08.013
[42] D. S. Waldenmaier, A. Babarina and F. C. Kischkel, “Rapid in Vitro Chemosensitivity Analysis of Human Colon Tumor Cell Lines,” Toxicology and Applied Pharmacology, Vol. 192, No. 3, 2003, pp. 237-245. doi:10.1016/S0041-008X(03)00257-6
[43] R. D. Blumenthal, “An Overview of Chemosensitivity Testing,” Methods in Molecular Medicine, Vol. 110, 2005, pp. 3-18.
[44] B. Tegze, Z. Szállási, I. Haltrich, Z. Pénzváltó and Z. Tóth, “Parallel Evolution under Chemotherapy Pressure in 29 Breast Cancer Cell Lines Results in Dissimilar Mechanisms of Resistance,” PLoS One, Vol. 7, No. 2, 2012, Article ID: e30804. doi:10.1371/journal.pone.0030804
[45] A. Bagnato and L. Rosanó, “Understanding and Overcoming Chemoresistance in Ovarian Cancer: Emerging Role of the Endothelia Axis,” Current Oncology, Vol. 19, No. 1, 2012, pp. 36-38. doi:10.3747/co.19.895

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.